Recovery From Anthracycline Cardiomyopathy After Long-term Support With a Continuous Flow Left Ventricular Assist Device

Mark Freilich, Dion Stub, Donald Esmore, Justin Negri, Robert Salamonsen, Peter Bergin, Angeline Leet, Meroula Richardson, Andrew Taylor, John Woodard, David Kaye, Franklin Rosenfeldt

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We report the clinical course of a 16-year-old girl in remission from non-Hodgkin's lymphoma who presented in cardiogenic shock due to a severe anthracycline cardiomyopathy. The patient was initially stabilized using central extracorporeal membrane oxygenation support, followed by conversion to a left ventricular assist device. Unexpected evidence of cardiac recovery 9 months after implant enabled device weaning during a 3-month period, culminating in successful device explantation 1 year after implant. The patient survives 18 months after explant in New York Heart Association class I, on conventional heart failure medical management and metabolic therapy.

Original languageEnglish
Pages (from-to)101-103
Number of pages3
JournalJournal of Heart and Lung Transplantation
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2009
Externally publishedYes

Cite this

@article{b430e948d2ff4d7ebb54d2cba0d4bdc4,
title = "Recovery From Anthracycline Cardiomyopathy After Long-term Support With a Continuous Flow Left Ventricular Assist Device",
abstract = "We report the clinical course of a 16-year-old girl in remission from non-Hodgkin's lymphoma who presented in cardiogenic shock due to a severe anthracycline cardiomyopathy. The patient was initially stabilized using central extracorporeal membrane oxygenation support, followed by conversion to a left ventricular assist device. Unexpected evidence of cardiac recovery 9 months after implant enabled device weaning during a 3-month period, culminating in successful device explantation 1 year after implant. The patient survives 18 months after explant in New York Heart Association class I, on conventional heart failure medical management and metabolic therapy.",
author = "Mark Freilich and Dion Stub and Donald Esmore and Justin Negri and Robert Salamonsen and Peter Bergin and Angeline Leet and Meroula Richardson and Andrew Taylor and John Woodard and David Kaye and Franklin Rosenfeldt",
year = "2009",
month = "1",
doi = "10.1016/j.healun.2008.10.002",
language = "English",
volume = "28",
pages = "101--103",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier",
number = "1",

}

Recovery From Anthracycline Cardiomyopathy After Long-term Support With a Continuous Flow Left Ventricular Assist Device. / Freilich, Mark; Stub, Dion; Esmore, Donald; Negri, Justin; Salamonsen, Robert; Bergin, Peter; Leet, Angeline; Richardson, Meroula; Taylor, Andrew; Woodard, John; Kaye, David; Rosenfeldt, Franklin.

In: Journal of Heart and Lung Transplantation, Vol. 28, No. 1, 01.2009, p. 101-103.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Recovery From Anthracycline Cardiomyopathy After Long-term Support With a Continuous Flow Left Ventricular Assist Device

AU - Freilich, Mark

AU - Stub, Dion

AU - Esmore, Donald

AU - Negri, Justin

AU - Salamonsen, Robert

AU - Bergin, Peter

AU - Leet, Angeline

AU - Richardson, Meroula

AU - Taylor, Andrew

AU - Woodard, John

AU - Kaye, David

AU - Rosenfeldt, Franklin

PY - 2009/1

Y1 - 2009/1

N2 - We report the clinical course of a 16-year-old girl in remission from non-Hodgkin's lymphoma who presented in cardiogenic shock due to a severe anthracycline cardiomyopathy. The patient was initially stabilized using central extracorporeal membrane oxygenation support, followed by conversion to a left ventricular assist device. Unexpected evidence of cardiac recovery 9 months after implant enabled device weaning during a 3-month period, culminating in successful device explantation 1 year after implant. The patient survives 18 months after explant in New York Heart Association class I, on conventional heart failure medical management and metabolic therapy.

AB - We report the clinical course of a 16-year-old girl in remission from non-Hodgkin's lymphoma who presented in cardiogenic shock due to a severe anthracycline cardiomyopathy. The patient was initially stabilized using central extracorporeal membrane oxygenation support, followed by conversion to a left ventricular assist device. Unexpected evidence of cardiac recovery 9 months after implant enabled device weaning during a 3-month period, culminating in successful device explantation 1 year after implant. The patient survives 18 months after explant in New York Heart Association class I, on conventional heart failure medical management and metabolic therapy.

UR - http://www.scopus.com/inward/record.url?scp=58149233908&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2008.10.002

DO - 10.1016/j.healun.2008.10.002

M3 - Article

VL - 28

SP - 101

EP - 103

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 1

ER -